Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T lymphocyte activation (delayed-type hypersensitivity) (DTH)
- Target
- DTH
- Molecular classification
- Immune response, Cell signaling pathway
01
Overview
T lymphocyte activation in the context of delayed-type hypersensitivity (DTH), also known as Type IV hypersensitivity, refers to a cell-mediated immune response that typically develops 24–72 hours after exposure to an antigen. Unlike antibody-mediated responses, DTH is driven by T cells—primarily CD4+ Th1 and CD8+ cytotoxic T cells—and involves the recruitment and activation of macrophages and other inflammatory cells at the site of antigen exposure.
- Other names
- Type IV hypersensitivityCell-mediated hypersensitivity
02
Mechanism of action
Suppression of local inflammation
03
Biological functions
Defense against intracellular pathogensImmune response to chemicals, drugs, and allergensCell-mediated immunityInflammation
04
Disease associations
Allergic contact dermatitisDrug eruptionsAsthmaAutoimmune diseasesTuberculosisGraft rejection
05
Safety considerations
Excessive inflammation leading to tissue damageDysregulation leading to autoimmune disorders
06
Interacting drugs
Topical corticosteroids
Beyond the preview
Go deeper on T lymphocyte activation (delayed-type hypersensitivity) (DTH).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T lymphocyte activation (delayed-type hypersensitivity) (DTH).